After 6 months of oral administration of nanocurcumin, MS patients showed a significant decrease in Th17-associated parameters, such as Th17 frequency, RAR-related orphan receptor γt (RORγt), and IL-17 expression and secretion levels [166]. Here, IL17A is linked to myeloid sarcoma.